一分钟看懂
这是一项关于胃癌的I 期 / II 期研究，登记的药物或干预包括AZD5863；AZD2936，当前状态为招募中。登记地点显示中国北京、山东省有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
AZD5863；AZD2936 · I 期 / II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · 北京
- Research Site · 山东省
公开的入选条件
- * Age ≥ 18 at the time of signing the informed consent
- * Histologically confirmed diagnosis of adenocarcinoma of the stomach, gastro-esophageal junction, esophagus, or pancreas
- * Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- * Must show positive CLDN18.2 expression in tumor cells as determined by central immunohistochemistry (IHC)
- * Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening
- * Predicted life expectancy of ≥ 12 weeks
- * Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
- * Contraceptive use by men or women should be consistent with local regulations, as defined by the protocol
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06005493；登记信息更新于 2026-09-25。